Valeria Bertagnolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4665905/publications.pdf

Version: 2024-02-01

66 1,803 22 40 papers citations h-index g-index

66 66 1597
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype. Journal of Personalized Medicine, 2022, 12, 993.	1.1	3
2	Vav1 Sustains the In Vitro Differentiation of Normal and Tumor Precursors to Insulin Producing Cells Induced by all-Trans Retinoic Acid (ATRA). Stem Cell Reviews and Reports, 2021, 17, 673-684.	1.7	2
3	Targeting the Vav1/miRâ€'29b axis as a potential approach for treating selected molecular subtypes of tripleâ€'negative breast cancer. Oncology Reports, 2021, 45, .	1.2	4
4	The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma. Cancers, 2021, 13, 4355.	1.7	5
5	Ethanol-based garlic extract prevents malignant evolution of non-invasive breast tumor cells induced by moderate hypoxia. Biomedicine and Pharmacotherapy, 2021, 142, 112052.	2.5	5
6	The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2. Cells, 2021, 10, 3059.	1.8	8
7	UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines. Genes, 2021, 12, 1978.	1.0	5
8	Vav1 Down-Modulates Akt2 Expression in Cells from Pancreatic Ductal Adenocarcinoma: Nuclear Vav1 as a Potential Regulator of Akt Related Malignancy in Pancreatic Cancer. Biomedicines, 2020, 8, 379.	1.4	6
9	Pulsed Electromagnetic Fields Modulate miRNAs During Osteogenic Differentiation of Bone Mesenchymal Stem Cells: a Possible Role in the Osteogenic-angiogenic Coupling. Stem Cell Reviews and Reports, 2020, 16, 1005-1012.	1.7	18
10	Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative Induces Differentiation-Coupled Apoptosis of Immature Myeloid Cells Such as Acute Myeloid Leukemia and Myeloid-Derived Suppressor Cells. International Journal of Molecular Sciences, 2020, 21, 5135.	1.8	6
11	Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells. Scientific Reports, 2020, 10, 2574.	1.6	11
12	CD133 in Breast Cancer Cells: More than a Stem Cell Marker. Journal of Oncology, 2019, 2019, 1-8.	0.6	76
13	Ectopic expression of PLCâ€Î²2 in nonâ€invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miRâ€146a. Molecular Carcinogenesis, 2019, 58, 708-721.	1.3	8
14	Clusterin enhances AKT2â€mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. Journal of Cellular Physiology, 2019, 234, 11188-11199.	2.0	19
15	Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome. Molecular Oncology, 2018, 12, 1012-1025.	2.1	5
16	Vav1 is necessary for PU .1 mediated upmodulation of miRâ€29b in acute myeloid leukaemiaâ€derived cells. Journal of Cellular and Molecular Medicine, 2018, 22, 3149-3158.	1.6	11
17	Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells. BMC Cancer, 2018, 18, 1194.	1.1	12
18	Levels of miR-126 and miR-218 are elevated in ductal carcinoma <i>in situ</i> (DCIS) and inhibit malignant potential of DCIS derived cells. Oncotarget, 2018, 9, 23543-23553.	0.8	12

#	Article	IF	CITATIONS
19	Up-modulation of PLC- \hat{l}^2 2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC. BMC Cancer, 2017, 17, 617.	1.1	24
20	A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report. Cellular Oncology (Dordrecht), 2016, 39, 483-489.	2.1	14
21	PLCâ€Î²2 is modulated by low oxygen availability in breast tumor cells and plays a phenotype dependent role in their hypoxiaâ€related malignant potential. Molecular Carcinogenesis, 2016, 55, 2210-2221.	1.3	11
22	hnRNP K in PU.1-containing complexes recruited at the CD11b promoter: a distinct role in modulating granulocytic and monocytic differentiation of AML-derived cells. Biochemical Journal, 2014, 463, 115-122.	1.7	13
23	High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process. Oncotarget, 2014, 5, 4320-4336.	0.8	27
24	In triple negative breast tumor cells, PLC- \hat{l}^2 2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness. Molecular Cancer, 2013, 12, 165.	7.9	41
25	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia, 2012, 26, 1301-1312.	3.3	78
26	Vav1 in differentiation of tumoral promyelocytes. Cellular Signalling, 2012, 24, 612-620.	1.7	20
27	Nuclear proteome analysis reveals a role of Vav1 in modulating RNA processing during maturation of tumoral promyelocytes. Journal of Proteomics, 2011, 75, 398-409.	1.2	11
28	Vav1: A Key Player in Agonist-Induced Differentiation of Promyelocytes from Acute Myeloid Leukemia (APL). , 2011, , .		0
29	Vav1 is a crucial molecule in monocytic/macrophagic differentiation of myeloid leukemia-derived cells. Cell and Tissue Research, 2011, 345, 163-175.	1.5	14
30	Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived promyelocytes: Role of Vav1 in modulating PU.1-containing complexes during ATRA-induced differentiation. Experimental Cell Research, 2010, 316, 38-47.	1.2	32
31	Mass Spectrometry-Based Identification of Y745 of Vav1 as a Tyrosine Residue Crucial in Maturation of Acute Promyelocytic Leukemia-Derived Cells. Journal of Proteome Research, 2010, 9, 752-760.	1.8	10
32	Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. Cell Research, 2009, 19, 1079-1089.	5.7	27
33	Vav1 Modulates Protein Expression During ATRA-Induced Maturation of APL-Derived Promyelocytes: A Proteomic-Based Analysis. Journal of Proteome Research, 2008, 7, 3729-3736.	1.8	22
34	Phospholipase C- \hat{l}^2 2 promotes mitosis and migration of human breast cancer-derived cells. Carcinogenesis, 2007, 28, 1638-1645.	1.3	62
35	PLC- \hat{l}^2 2 activity on actin-associated polyphosphoinositides promotes migration of differentiating tumoral myeloid precursors. Cellular Signalling, 2007, 19, 1701-1712.	1.7	9
36	PLC- \hat{l}^22 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. International Journal of Oncology, 2006, 28, 863.	1.4	13

3

#	Article	IF	CITATIONS
37	The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells. Leukemia, 2006, 20, 941-951.	3.3	49
38	Parallel regulation of PKC-α and PKC-δ characterizes the occurrence of erythroid differentiation from human primary hematopoietic progenitors. Experimental Hematology, 2006, 34, 1624-1634.	0.2	11
39	A flow cytometry procedure for simultaneous characterization of cell DNA content and expression of intracellular protein kinase C-ζ. Journal of Immunological Methods, 2006, 315, 37-48.	0.6	21
40	PLC- \hat{l}^2 2 monitors the drug-induced release of differentiation blockade in tumoral myeloid precursors. Journal of Cellular Biochemistry, 2006, 98, 160-173.	1.2	7
41	PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. International Journal of Oncology, 2006, 28, 863-72.	1.4	20
42	Vav promotes differentiation of human tumoral myeloid precursors. Experimental Cell Research, 2005, 306, 56-63.	1.2	25
43	Association of PI 3-K with tyrosine phosphorylated Vav is essential for its activity in neutrophil-like maturation of myeloid cells. Cellular Signalling, 2004, 16, 423-433.	1.7	34
44	Ornithine decarboxylase, polyamines and CD11b expression in HL-60 cells during differentiation induced by retinoic acid. Biomedicine and Pharmacotherapy, 2004, 58, 401-406.	2.5	5
45	Selective up-regulation of phospholipase C-beta2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors. Journal of Leukocyte Biology, 2002, 71, 957-65.	1.5	11
46	Fhit protein expression in human gastric cancer and related precancerous lesions. Oncology Reports, 2001, 8, 1233-7.	1.2	6
47	Selective modulation of specific protein kinase C (PKC) isoforms in primary human megakaryocytic vs. erythroid cells., 1999, 255, 7-14.		12
48	Monocytic Differentiation of HL-60 Cells Is Characterized by the Nuclear Translocation of Phosphatidylinositol 3-Kinase and of Definite Phosphatidylinositol-Specific Phospholipase C Isoforms. Biochemical and Biophysical Research Communications, 1999, 259, 314-320.	1.0	32
49	Nuclear association of tyrosine-phosphorylated Vav to phospholipase C-γ1 and phosphoinositide 3-kinase during granulocytic differentiation of HL-60 cells. FEBS Letters, 1998, 441, 480-484.	1.3	48
50	Phosphatidylinositol 3-Kinase in HL-60 Nuclei Is Bound to the Nuclear Matrix and Increases During Granulocytic Differentiation. Biochemical and Biophysical Research Communications, 1998, 253, 346-351.	1.0	57
51	Intranuclear Translocation of Phospholipase C \hat{l}^2 2 during HL-60 Myeloid Differentiation. Biochemical and Biophysical Research Communications, 1997, 235, 831-837.	1.0	42
52	Changes of Nuclear PI-PLC Î ³ 1 During Rat Liver Regeneration. Cellular Signalling, 1997, 9, 353-362.	1.7	37
53	Low Nanogram Range Quantitation of Diglycerides and Ceramide by High-Performance Liquid Chromatography. Analytical Biochemistry, 1996, 233, 108-114.	1.1	66
54	Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid. British Journal of Haematology, 1996, 93, 542-550.	1.2	61

#	Article	IF	CITATIONS
55	Identification of PI-PLC \hat{i}^21 , \hat{i}^31 , and $\hat{i}'1$ in rat liver: Subcellular distribution and relationship to inositol lipid nuclear signalling. Cellular Signalling, 1995, 7, 669-678.	1.7	46
56	Inositol lipid phosphorylation and breakdown in rat liver nuclei is affected by hydrocortisone blood levels. Cell Biochemistry and Function, 1994, 12, 201-207.	1.4	7
57	Diacylglycerol kinase activity in rat liver nuclei. Cellular Signalling, 1994, 6, 393-403.	1.7	13
58	Discrete subcellular localization of phosphoinositidase C \hat{l}^2 , \hat{l}^3 and \hat{l}' in PC12 rat pheochromocytoma cells. Biochemical and Biophysical Research Communications, 1992, 187, 114-120.	1.0	60
59	Nuclear localization and signalling activity of phosphoinositidase $\hat{Cl^2}$ in Swiss 3T3 cells. Nature, 1992, 358, 242-245.	13.7	329
60	Increased phosphorylation of nuclear substrates for rat brain protein kinase C in regenerating rat liver nuclei. Cellular Signalling, 1992, 4, 313-319.	1.7	10
61	In vitro phosphorylation of lamin B by protein kinase C in friend erythroleukemia. Effect of chemically induced differentiation. Cell Biology International Reports, 1991, 15, 409-426.	0.7	7
62	Inositol lipids in friend erythroleukemia cells: Evidence for changes in nuclear metabolism after differntiation. Cell Biochemistry and Function, 1991, 9, 135-145.	1.4	13
63	Nuclear inositol lipids in friend erythroleukemia cells. Changes related to differentiation induced by hexamethylenebisacetamide. Cell Biology International Reports, 1990, 14, 783-795.	0.7	17
64	Uptake and phosphorylation of phosphatidylinositol by rat liver nuclei. Role of phosphatidylinositol transfer protein. Lipids and Lipid Metabolism, 1990, 1044, 193-200.	2.6	49
65	Lipid phosphorylation in isolated rat liver nuclei Synthesis of polyphosphoinositides at subnuclear level. FEBS Letters, 1989, 254, 194-198.	1.3	48
66	Two TaqI RFLPs in the human von Willebrand factor gene. Nucleic Acids Research, 1987, 15, 1347-1347.	6.5	16